

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2015 OS PC

DESPATCHED ON 19TH MAY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A66; B35, B70; Cw4, Cw12; DR1, DR7; DQ2, DQ5

			Summary of Results							
			PBL/T-Cells				B-Cells			
Total tested			28	30	29	30	21	23	23	23
Positive			22	0	5	0	18	2	17	1
Negative			6	30	24	30	3	21	6	22
NT/Equivocal			6	4	5	4	4	2	2	2
% Positive			78.6%	0.0%	17.2%	0.0%	85.7%	8.7%	73.9%	4.3%
% Negative			21.4%	100.0%	82.8%	100.0%	14.3%	91.3%	26.1%	95.7%
Consensus			Positive	Negative	Negative	Negative	Positive	Negative	Not Assessed	Negative
HLA Antibody Specificity (Defined By CDC)			A3	A1, DR3	B17	A24	A3	A1, DR3	B17	A24
			Without DTT				Without DTT			
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
112	YES	NO	NT	NT	NT	NT				
116	YES	NO	Positive	Negative	Positive	Negative				
119	YES	NO	Positive	Negative	Positive	Negative				
120	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
126	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
128	YES	NO	Negative	Negative	Negative	Negative				
139	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
143	YES	NO	Positive	Negative	Negative	Negative				
147	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
154	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
157	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
159	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
174	YES	NO	NT	NT	NT	NT				
181	YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Positive	Negative
189	YES	YES	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative
190	YES	YES	Negative	Negative	Negative	Negative	NT	Negative	Positive	Negative
193	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
194	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
195	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
197	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative
209	YES	YES	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive
216	YES	NO	Positive	Negative	Negative	Negative				
223	YES	YES	Positive	Negative	Negative	Negative	NT	NT	NT	NT
229	YES	NO	Positive	Negative	Positive	Negative				
232	YES	NO	NT	NT	NT	NT				
238	YES	YES	Positive	Negative	Equivocal	Negative	Positive	Negative	Positive	Negative
245	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
252	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
259	YES	YES	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
262	YES	YES	Equivocal	Negative	Negative	Negative	Positive	Negative	Positive	Negative
293	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
294	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
297	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative

The samples arrived 28th May, probably due to a customs strike. Therefore cells not viable.

Samples delayed due to customs. Serum 1 - Results non interpretable. Not enough serum to repeat

2A delivered late, possibly due to airline problem.

B-cells not tested due to low viability

This sample could not be tested as the lymphocytes were non-viable

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2015 OS PC

DESPATCHED ON 19TH MAY 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT					40		
116	8	1	2	1						95	
119	6	1	2	1					90		
120	6	1	1	1	6	1	8	1		100	100
126	52%	0%	0%	1%	43%	2%	55%	2%		95	95
128	1	1	1	1					96		
139	4	1	1	1	6	1	8	1		99	99
143	8	1	1	1						95	
147	8	1	1	1	8	1	8	1		100	100
154	4	1	1	1	8	1	8	1		95	95
157	6	1	1	1	6	1	1	1	100	100	100
159	6	1	1	1	6	1	8	1		100	90
174	NT	NT	NT	NT							
181		1	1	1		1	4	1	100		100
189	6	1	6	1	6	6	6	1	90	85	88
190	5%	5%	5%	5%	NT	10%	90%	10%		95	90
193	8	1	1	1	4	1	6	1		98	98
194	6	1	1	1	8	1	6	1	93		
195	NT	NT	NT	NT	NT	NT	NT	NT			
197					Strong		Weak		90	80	80
209	8				8	2	8	4	80		90
216	4	1	2	1					95		
223	8	2	2	1	NT	NT	NT	NT		95	75
229	80%		30%						90		
232	NT	NT	NT	NT					0		
238	8	1	2	1	8	1	8	1	98	98	90
245	1	1	1	1	1	1	1	1	100	100	100
252	4-6	1	1	1	4-6	1	1	1	60		50
259									90	85	85
260										90	50
262					8		8		100		
293	8+				8+					50	50
294	6	0	0	0	6	0	4	0		100	100
297	6	1	1	1	8	2	6	1	90	90	90

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2015 OS PC

DESPATCHED ON 19TH MAY 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A66; B35, B70; Cw4, Cw12; DR1, DR7; DQ2, DQ5

			Summary of Results							
			PBL/T-Cells				B-Cells			
Total tested	20	22	22	22	18	20	20	20		
Positive	17	0	3	0	16	1	15	1		
Negative	3	22	19	22	2	19	5	19		
NT/Equivocal	7	5	5	5	4	2	2	2		
% Positive	85.0%	0.0%	13.6%	0.0%	88.9%	5.0%	75.0%	5.0%		
% Negative	15.0%	100.0%	86.4%	100.0%	11.1%	95.0%	25.0%	95.0%		
Consensus	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative		
HLA Antibody Specificity (Defined By CDC)	A3	A1, DR3	B17	A24	A3	A1, DR3	B17	A24		
			With DTT				With DTT			
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
112	YES	NO	NT	NT	NT	NT				
116	YES	NO	Positive	Negative	Positive	Negative				
119	YES	NO	NT	NT	NT	NT				
120	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
139	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
147	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
154	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
157	NO	YES					Positive	Negative	Negative	Negative
159	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
174	YES	NO	NT	NT	NT	NT				
181	YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Positive	Negative
189	YES	YES	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative
190	YES	YES	Negative	Negative	Negative	Negative	NT	Negative	Positive	Negative
193	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
194	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
195	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
197	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative
209	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Positive
216	YES	NO	Positive	Negative	Negative	Negative				
229	YES	NO	Positive	Negative	Positive	Negative				
238	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
245	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative
252	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
262	YES	YES	Equivocal	Negative	Negative	Negative	Positive	Negative	Positive	Negative
293	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative
294	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative
297	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative

DTT not tested due to technical problems

Insufficient cells

Samples delayed due to customs.
Serum 1 - Results non interpretable. Not enough serum to repeat

2A delivered late, possibly due to airline problem.

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2015 OS PC

DESPATCHED ON 19TH MAY 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	NT	NT	NT	NT					40		
116	8	1	2	1						95	
119	NT	NT	NT	NT					90		
120	8	1	1	1	6	1	8	1		100	100
139	4	1	1	1	6	1	8	1		99	99
147	8	1	1	1	8	1	8	1		100	100
154	NT	NT	NT	NT	NT	NT	NT	NT		95	95
157					6	1	1	1	100	100	100
159	6	1	1	1	4	1	6	1		100	90
174	NT	NT	NT	NT							
181		1	1	1		1	4	1	100		100
189	6	1	6	1	6	6	6	1	90	85	88
190	5%	5%	5%	5%		10%	90%	10%		95	90
193	8	1	1	1	4	1	6	1		98	98
194	4	1	1	1	6	1	6	1	93		
195	NT	NT	NT	NT	NT	NT	NT	NT			
197					Weak		Weak		90	80	80
209	4				4		8	2	80		90
216	4	1	2	1					95		
229	80%		30%						90		
238	8	1	1	1	8	1	8	1	98	98	90
245	8	1	1	1	1	1	1	1	100	100	100
252	4-6	1	1	1	4-6	1	1	1	60		50
260										90	50
262					8		8		100		
293	8+				8+					50	50
294	6	0	0	0	6	0	4	0		100	100
297	6	1	1	1	8	2	6	1	90	90	90